Premium
Effects of the route of oestrogen administration on IGF‐1 and IGFBP‐3 in healthy postmenopausal women: results from a randomized placebo‐controlled study
Author(s) -
Sonnet Emmanuel,
Lacut Karine,
Roudaut Nathalie,
Mottier Dominique,
Kerlan Véronique,
Oger Emmanuel
Publication year - 2007
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2007.02783.x
Subject(s) - transdermal , placebo , medicine , endocrinology , estrogen , hormone replacement therapy (female to male) , postmenopausal women , hypoestrogenism , oral administration , menopause , randomized controlled trial , pharmacology , testosterone (patch) , alternative medicine , pathology
Summary Objective Oestrogens can modulate the action or secretion of GH. Previous studies in postmenopausal women have shown a differential effect between transdermal 17β‐oestradiol and oral ethynyl‐oestradiol on GH and IGF‐1 concentrations. This secondary analysis, based on a large randomized trial, aimed to estimate the effect of the route of administration of 17β‐oestradiol in combined hormone replacement therapy with progesterone on IGF‐1 and IGFBP‐3 levels. Design IGF‐1 and IGFBP‐3 were evaluated in a randomized study of 196 healthy postmenopausal women who were randomly allocated to receive on a continuous basis either 1 mg of 17β‐oestradiol orally combined with a daily intake of 100 mg progesterone (group 1; n = 63), or 50 µg of 17β‐oestradiol transdermally combined with a daily intake of 100 mg progesterone (group 2; n = 68), or triple dummy placebo (group 3; n = 65) over a 6‐month period. IGF1 and IGFBP‐3 levels were available for 133 women. Results Oral oestrogen significantly decreased IGF‐1 levels compared to placebo ( P = 0·04) and transdermal oestrogen ( P = 0·004), whereas transdermal oestrogen had no effect on IGF‐1 levels compared to placebo ( P = 0·56). As regards IGFBP‐3, no significant difference was detected between the three groups. Conclusions Our data indicate that the route of oestrogen administration can influence IGF‐1 levels. IGF‐1 concentrations decreased significantly with oral oestrogen, whereas no significant change was observed with transdermal oestrogen at 6 months. The clinical relevance of these differential effects remains to be determined, particularly with regard to the risk for cardiovascular diseases.